ELF3 is altered in 2.80% of all cancers with breast invasive ductal carcinoma, bladder urothelial carcinoma, lung adenocarcinoma, colon adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations .
The most common alterations in ELF3 are ELF3 Amplification (1.42%), ELF3 Mutation (0.81%), ELF3 Loss (0.04%), ELF3 X160_splice (0.02%), and ELF3 M324I (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.